Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
Oncotarget|August 6, 2015
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphomaNina A Sibbesen, Katharina L Kopp, Ivan V Litvinov, et al.
Blood Cancer Journal|May 16, 2020
Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndromeAndreas Willerslev-Olsen, Terkild B Buus, Claudia Nastasi, et al.
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Blood|May 12, 2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyVijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, et al.
The Journal of Investigative Dermatology|May 12, 2018
SATB1 in Malignant T CellsSimon Fredholm, Andreas Willerslev-Olsen, Özcan Met, et al.
Oncotarget|June 23, 2016
STAT5 induces miR-21 expression in cutaneous T cell lymphomaLise M Lindahl, Simon Fredholm, Claudine Joseph, et al.
Blood|May 23, 2018
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitorsSilvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, et al.
Cell Reports|October 7, 2020
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow MicroenvironmentBac Viet Le, Paulina Podszywalow-Bartnicka, Silvia Maifrede, et al.
Blood|August 26, 2011
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)Ulrik Ralfkiaer, Peter H Hagedorn, Nannie Bangsgaard, et al.
Pageof 12